A combination of two cancer drugs may provide a pathway to treat Alzheimer’s, according to a study published July 21 in Cell.
Researchers from the University of California San Francisco developed and applied a computational drug repurposing algorithm to 1,300 FDA-approved drugs or previously investigated compounds with the aim of identifying drugs that could potentially be repurposed.
Here are three notes from the study:
- Two drugs — the breast cancer drug letrozole, and the colon and lung cancer drug irinotecan — were identified as possible options as they target Alzheimer’s-related gene expression changes.
- When combined, the drugs seemed to slow or reverse Alzheimer’s disease symptoms in mice.
- “These results highlight the promise of cell-type-directed combination therapies in addressing multifactorial diseases like Alzheimer’s disease and lay the groundwork for precision medicine tailored to patient-specific transcriptomic and clinical profiles,” the study authors wrote.
Read the full study here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
